9350 Kirby Drive
Suite 300
Houston, TX 77054
United States
713 400 6400
https://markertherapeutics.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 8
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Juan F. Vera M.D. | Co-Founder, CEO, President, Treasurer, Secretary & Director | 372,1k | S.O. | 1980 |
Ms. Elizabeth Donnelly | Director of Administration | S.O. | S.O. | S.O. |
Dr. Robert Z. Florkiewicz Sr. | Senior Director of Molecular Biology & Virology | S.O. | S.O. | S.O. |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
L’ISS Governance QualityScore de Marker Therapeutics, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..